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Mutation screening of the breast and ovarian cancer–predisposition genes BRCA1 and BRCA2 is becoming an increasingly
important part of clinical practice. Classification of rare nontruncating sequence variants in these genes is problematic,
because it is not known whether these subtle changes alter function sufficiently to predispose cells to cancer development.
Using data from the Myriad Genetic Laboratories database of nearly 70,000 full-sequence tests, we assessed the clinical
significance of 1,433 sequence variants of unknown significance (VUSs) in the BRCA genes. Three independent measures
were employed in the assessment: co-occurrence in trans of a VUS with known deleterious mutations; detailed analysis,
by logistic regression, of personal and family history of cancer in VUS-carrying probands; and, in a subset of probands,
an analysis of cosegregation with disease in pedigrees. For each of these factors, a likelihood ratio was computed under
the hypothesis that the VUSs were equivalent to an “average” deleterious mutation, compared with neutral, with respect
to risk. The likelihood ratios derived from each component were combined to provide an overall assessment for each
VUS. A total of 133 VUSs had odds of at least 100:1 in favor of neutrality with respect to risk, whereas 43 had odds of
at least 20:1 in favor of being deleterious. VUSs with evidence in favor of causality were those that were predicted to
affect splicing, fell at positions that are highly conserved among BRCA orthologs, and were more likely to be located in
specific domains of the proteins. In addition to their utility for improved genetics counseling of patients and their
families, the global assessment reported here will be invaluable for validation of functional assays, structural models,
and in silico analyses.
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Sequence-based testing for BRCA1 (MIM 113705) and
BRCA2(MIM 600185) mutations is now widely available
through both commercial laboratories and research stud-
ies. Whereas thousands of BRCA1 and BRCA2 truncating
mutations have been associated with increased risk of
cancer in carriers, the contribution of other BRCA1 and
BRCA2 sequence variants to cancer risk remains largely
undefined. These “variants of unknown significance”
(VUSs) are mainly missense mutations but also include a
number of intronic variants and inframe deletions and
insertions (IFDIs). The open-access online Breast Cancer
Information Core (BIC) Database, which functions as a
repository of sequence alterations in BRCA1 and BRCA2,
contains 11,500 distinct sequence variants that are cur-
rently reported as having unknown clinical significance.
To date, classification of the BRCA1 and BRCA2 VUSs as
cancer predisposing or neutral has proven problematic,
because it is not known whether these subtle changes alter
the function of the proteins sufficiently to predispose to
cancer. Determination of their disease relevance on the
basis of population or family studies has also proved dif-
ficult, because most of the alleles encoding these muta-
tions are very rare and, in some cases, population specific.
Although identified in a minority (5%–10%) of individuals
tested clinically, the number of such tests performed an-
nually worldwide means that a large number of women
(and their families) are affected by the VUS issue. In ad-
dition, there is evidence to suggest that minority ethnic
populations are disproportionately affected. VUSs in the
BRCA1 and BRCA2 genes pose significant problems, be-
cause patients and physicians do not know whether the
VUSs predispose to cancer or are neutral with respect to
cancer risk. As a result, carriers of VUSs and their family
members cannot take advantage of the risk assessment,
prevention, and therapeutic measures that are available
to carriers of known deleterious truncating mutations.1 In
addition, carriers of VUSs are sometimes counseled to un-
dergo prophylactic oophorectomy or mastectomy because
of the presence of the VUS, but in the absence of any
knowledge of the cancer relevance of the VUS. For these
reasons, the determination of the clinical relevance of
VUSs in BRCA1 and BRCA2 has become an important clin-
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Table 1. Results of Full BRCA Sequence Analysis of 60,529 Tested Probands
Ethnic Group
No. (%) of Subjects with Genotype
Wild Type Neutral VUS
BRCA1
Deletion
BRCA2
Deletion
Europeana 41,899 (78.6) 1,993 (3.7) 3,972 (7.5) 3,102 (5.8) 2,334 (4.4)
Ashkenazi Jewish 3,622 (80.6) 381 (8.5) 258 (5.7) 139 (3.1) 91 (2.0)
African American/Caribbean 1,667 (60.9) 398 (14.5) 393 (14.3) 176 (6.4) 104 (3.8)
Total 47,188 (78.0) 2,772 (4.6) 4,623 (7.6) 3,417 (5.6) 2,529 (4.2)
a See the text for the description of ethnicity for this group.
ical issue. Although the focus of this article is on BRCA1
and BRCA2, similar concerns and issues are found in vir-
tually all complex, genetically heterogeneous diseases for
which genetic testing is performed—for example, colon
cancer associated with mutations in mismatch repair
genes.2
To address the problem of defining which VUSs are del-
eterious/disease causing and which are neutral, various
types of evidence and classification schemes have been
proposed.3–5 These include formal assessment of the co-
segregation of the variant with disease in pedigrees,6–8 co-
occurrence of the variant in question in trans with a
known deleterious mutation,9 and a number of in silico
approaches that evaluate phylogenetic conservation and
severity of the amino acid substitution.10–12 In studies of
other genes, evolutionary sequence-conservation analysis
involving protein multiple-sequence alignments have been
used to show that missense variants (MVs) at highly con-
served/invariant residues are more often deleterious, where-
as highly variable changes are more likely neutral.13,14 For
BRCA1, Abkevich et al.10 developed a predictive algorithm
that combines a measure of cross-species conservation,
including nonmammalian BRCA1 sequences, with a mea-
sure of the degree of chemical change in amino acids,15 to
identify 50 putative deleterious BRCA1 missense mutations.
A number of VUSs have been examined, in terms of
their effect on protein, with use of functional assays. Ef-
forts in this area have focused on BRCA1 mutations in the
two C-terminal BRCT domains,16,17 which assess the tran-
scriptional activation activity of the BRCT domains with
use of mammalian and yeast-based models,18–20 and on the
E3 ligase activity associated with the N-terminal BARD1-
binding domain of BRCA1.21 Examination of BRCA2 func-
tion has focused on assays of homology-directed repair
and centrosome amplification in response to ectopic ex-
pression of full-length, wild-type VUS containing BRCA2
protein.22 Recently, crystal structures of the BRCA1 BRCT
and BRCA2 DNA-binding domains have been used to pre-
dict that a number of VUSs predispose to cancer,23–25 but
genetic evidence suggests that some of these predictions
are incorrect. Although none of the approaches described
above have successfully been used to classify the clinical
relevance of BRCA1 or BRCA2 VUSs, a number have shown
promise in this regard. The development of methods based
on functional assays, crystal structure, phylogenetic and
sequence analyses, and other approaches has been ham-
pered by the absence of a large number of VUSs that have
been proven to be either deleterious or neutral on the basis
of direct genetic evidence that can be used in validation
of these various assays.
In this article, we examine the genetic evidence for or
against disease causality for a large number of variants,
with use of a large database of tested individuals collected
by Myriad Genetic Laboratories. In addition to analysis of
co-occurrence of VUSs with established deleterious muta-
tions and the analysis of VUS cosegregation in individual
pedigrees, we apply a novel analysis of personal and family
cancer history, using data on 170,000 individuals, to assess
the clinical significance of 1,433 distinct sequence variants
in BRCA1 and BRCA2.
Methods
Source of Data and Variants Analyzed
The data analyzed for this article come from the large database
of full-sequence testing for mutations in the BRCA1 and BRCA2
genes, performed at Myriad Genetic Laboratories. Since our pri-
mary focus was on the analysis of personal and family history,
we began with all 70,071 individuals receiving full-sequence tests
as of December 2005. To avoid potential confusion over which
part of the personal/family history was due to which variant, this
data set was reduced by eliminating all individuals who had more
than one reported sequence variant (including both VUS and
pathogenic mutations), which resulted in a set of 61,270 indi-
viduals with at most a single BRCA1 or BRCA2 sequence variant.
We then divided the family history data set into several ethnic
groups, since we postulated that probands of different ethnic
backgrounds are expected to present with different distributions
of mutations and different distributions of personal and family
histories of cancer. After examining the data set with use of some
preliminary logistic regressions to examine heterogeneity as a
function of reported ethnicity, we constructed three separate
groups that had similar family-history and mutation-prevalence
profiles. These groups were: (a) western European, central/eastern
European, other/none specified, Native American, and Asian; (b)
Ashkenazi Jewish; and (c) Latin American/Caribbean and African
American. In the first group, 72% were of European ancestry, 24%
did not specify an ethnicity, and 4% were reported as of Asian,
Middle Eastern, or Native American origin. Individual probands
who reported mixed ancestry between these broad groups (e.g.,
Western European and Caribbean) were not included in the final
data set, leaving 60,529 individual probands for analyses of family
history. Table 1 shows the distribution by ethnicity and testing
results of these individuals. A total of 1,433 distinct unclassified
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Table 2. ORs and Associated 95% CIs from Logistic-Regression Analysis
of the Myriad Genetic Laboratories Family-History Data of 47,335 White
Probands
History and Cancer Type (Age at
Onset, in Years)
OR (95% CI) for Gene versus Wild Type
BRCA1 BRCA2
Personal history of cancer for proband:
DCIS only 1.58 (1.2–2.1) 2.34 (1.9–2.9)
BRCA (60) 1.25 (1.0–1.6) 1.55 (1.3–1.9)
BRCA (50–59) 1.67 (1.4–2.0) 2.07 (1.7–2.5)
BRCA (40–49) 3.40 (3.0–3.9) 2.89 (2.5–3.4)
BRCA (30–39) 9.65 (8.4–11.1) 4.97 (4.2–5.8)
BRCA (!30) 15.3 (12.4–19.1) 4.71 (3.5–6.4)
Bilateral BRCA 2.40 (2.1–2.7) 1.46 (1.3–1.7)
Male BRCA 1.91 (.9–4.1) 12.0 (8.9–16.3)
Ovarian (60) 4.60 (3.7–5.8) 4.52 (3.6–5.7)
Ovarian (50–59) 11.8 (9.7–14.4) 7.92 (6.4–9.8)
Ovarian (40–49) 18.0 (14.8–21.9) 4.05 (3.0–5.5)
Ovarian (!40) 7.06 (5.1–9.8) .52 (.18–1.36)
Family history of cancera:
1 BRCA (!50) 2.16 (1.9–2.5) 1.82 (1.6–2.1)
2 BRCA (!50) 3.33 (3.0–3.7) 2.20 (2.0–2.5)
3 BRCA (!50) 5.60 (4.7–6.7) 3.84 (3.2–4.6)
4 BRCA (!50) 8.31 (7.2–9.8) 4.20 (3.5–5.0)
1 BRCA (50) .92 (.82–1.04) 1.26 (1.1–1.4)
2 BRCA (50) .82 (.73–.93) 1.36 (1.2–1.5)
3 BRCA (50) .75 (.6–.94) 1.45 (1.2–1.7)
4 BRCA (50) .56 (.41–.57) 1.33 (1.1–1.7)
1 Ovarian 2.56 (2.2–2.9) 1.56 (1.3–1.8)
2 Ovarian 4.75 (4.2–5.3) 1.87 (1.6–2.2)
3 Ovarian 9.06 (7.3–11.3) 3.30 (2.5–4.4)
4 Ovarian 11.1 (8.5–14.4) 1.83 (1.2–2.9)
a Assessed as twice the number of first-degree relatives with given cancer type plus
the number of second-degree relatives with given cancer type.
variants in 4,623 tested probands were identified through se-
quencing and are the subject of this article.
As before,3 we assumed that all variants can be classified as
deleterious mutations (M) or neutral variants (V). Our aim was
to calculate a likelihood ratio (LR) of the form
P(DataFM)
P(DataFV)
for each variant, given the available data. These ratios (or Bayes
factors) can be combined with prior probabilities to obtain an
absolute probability that each variant is deleterious. In this work,
we first focused on the data sources that are most straightforwardly
quantifiable from pedigree data: co-occurrence with known dele-
terious mutations, family history, and cosegregation. These three
sources of data are independent, and the LR can therefore be
derived by multiplying the LRs from the three components. We
then used an admixture model to examine the influence of the
type of mutation.
Co-Occurrence with Known Deleterious Mutations
To include information on the co-occurrence of a VUS in trans
phase with a deleterious mutation as evidence against the variant
being disease causing, we followed the likelihood-ratio calcu-
lation described in our previous work.3 We assumed that, for
BRCA1, compound heterozygotes for two deleterious mutations
are vanishingly rare (occur in the testing population with a fre-
quency of 1 in 10,000), given both biological and genetic evi-
dence that homozygotes or compound heterozygotes for dele-
terious BRCA1 mutations are embryonically lethal,26,27 whereas,
for BRCA2, we assumed that the probability is 1 in 1,000, the
increased frequency reflecting the fact that viable compound het-
erozygotes have been reported as Fanconi anemia, type D1.28,29
For these analyses, we used an updated data set based on∼100,000
tests with observed frequencies of BRCA1 and BRCA2 deleterious
mutations of 6.6% and 5.0%, respectively. The phase of the VUS
with an observed deleterious mutation was determined through
examination of haplotypes of common polymorphisms known
in other examples of each variant or when the VUS and the del-
eterious mutation were in the same PCR fragment, as determined
by direct examination of the sequence traces. In some cases, phase
could not be determined, and we assumed that the first delete-
rious mutation was in cis phase and that subsequent different
deleterious mutations were in trans phase. The LR for deleterious
versus neutral is expressed as
k nk(p ) (1 p )2 2 ,k nkp (1 p )1 1
where n is the total number of times the variant was observed,
k is the number of those that were in trans with a known dele-
terious mutation, p1 is the overall frequency of pathogenic mu-
tations in the data set, and p2 is the probability of being a com-
pound heterozygote for two pathogenic mutations (e.g., p p1
and ).0.066 p p 1/10,0002
Of the 1,433 VUSs studied here, 476 were observed at least five
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times, and 248 had at least 10 occurrences. Of the 1,433 variants,
44 were observed to occur with at least one deleterious mutation.
Classification by Personal and Family History of Tested
Probands
We developed likelihood models on the basis of family history,3
which, given the availability of the large Myriad Genetic Labo-
ratories data set, is an extremely powerful tool for classification
of VUSs. The method is based on the difference in personal and
family-history profiles between individuals found to carry a true
deleterious mutation and those with a wild-type BRCA sequence.
The rationale is that mutation prevalence is known to be strongly
dependent on certain key factors (e.g., disease status of the pro-
band, age at diagnosis, and number and age of relatives with
breast cancer [BRCA] or ovarian cancer), so these characteristics
should also predict the probability of a new disease-causing mis-
sense mutation, whereas that of a neutral mutation should be
independent of family history.
We suppose that we have a set of probands drawn from a pop-
ulation with a certain distribution of family history. Suppose first
that family history is classified into n types. Let pj be the prob-
ability that an individual with a mutation has family history type
j, whereas qj is the corresponding probability for neutral variants.
For a VUS that is deleterious, the predicted distribution of family
history should be the same as that for known pathogenic mu-
tations. The LR for a VUS with family history in category j drawn
from the same population is therefore
( )P FH FM,{FH} pj jp ,( )P FH FV,{FH} qj j
where {FH} is the set of all family histories in the study popula-
tion. In theory, the probabilities pj and qj could be calculated from
the proportions of individuals with each category of family his-
tory who are found to carry a deleterious mutation. In practice,
however, there are large numbers of possible constellations of
family history, and the numbers of mutations in some categories
would be very small. Instead, we estimated these probabilities by
fitting a logistic-regression model. Thus, we fitted a model in which
the outcome was the occurrence of a deleterious mutation versus
a normal sequence, and summaries of personal and family history
were included as covariates.
This model then provides predicted probabilities rk that indi-
vidual k is a mutation carrier, given his or her FH, is
{ }r p P MF FH .( )k k
Let r0 be the corresponding probability under the null hypoth-
esis that the mutation is unrelated to family history or, equiva-
lently, the prior probability of a deleterious mutation in the pop-
ulation. This is estimated by the overall proportion of individuals
who have a deleterious mutation (rather than a normal sequence).
For example, with use of the data in table 1, for the European
group for BRCA1,
3,102
r p p 0.069 .0 3,102 41,899
Then
{ } { }P MF FH P FH F{FH}( ) ( )k k( )p p P FH FM,{FH}pk k ( )P MF{FH}
( )r P FH F{FH}k kp
r0
and
( ) ( )P VFFH P [FH F{FH}k k{ }q p P FH FV,{FH} p( )k k ( )P VF{FH}
{ }(1 rk)P FH F{FH}( )k
p .
1 r0
Therefore, the required LR is
r (1 r )k 0 ;
(1 r )rk 0
that is, the odds ratio (OR) of the predicted probability that the
individual with the given family history is a mutation carrier
against the corresponding probability under the null hypothesis.
Where there are multiple individuals with the same VUS, the LRs
can be multiplied. We note that this formulation implicitly as-
sumes that all pathogenic mutations in the same gene confer
identical risks—that is, that there is no allelic heterogeneity.
To implement this analysis, the logistic-regression model was
fitted separately for each ethnic group and separately for BRCA1
and BRCA2. To construct a predictive model to be applied to the
VUS probands, we used a logistic-regression model within each
ethnic group, comparing the personal and family histories of in-
dividuals with known deleterious sequences versus those with
normal sequences. The specific factors used in the prediction were
categorized as
Personal history of tested individual
BRCA
1. None,
2. Ductal carcinoma in situ (DCIS) only, or
Diagnosis of BRCA at age
3. 60,
4. 50–59,
5. 40–49,
6. 30–39, or
7. !30.
Ovarian cancer
1. None or
Diagnosis of ovarian cancer at age
2. 60,
3. 50–59,
4. 40–49, or
5. !40.
Male BRCA
1. Yes or
2. No.
Bilateral BRCA
1. Yes or
2. No.
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and
Reported family history of tested proband (assessed as twice the
number of first-degree relatives with given cancer type plus the
number of second-degree relatives with given cancer type) (table
2).
In total, therefore, there were 24 parameters estimated in each
of six logistic regressions: BRCA1 versus wild type and BRCA2
versus wild type for each of the three ethnicity groupings. The
predicted probabilities pk were obtained using the “predict” op-
tion in STATA.
As a simple validation of the process outline above, we ex-
amined the family history ORs for the known deleterious variants.
Of the 1,106 distinct deleterious variants examined, 123 had odds
of 1100:1 in favor of being deleterious, 216 had odds of 110:1,
and no known variants were excluded at this same threshold.
Although we recognize that these summaries may overstate the
model’s out-of-sample predictive ability, since the deleterious var-
iants were used to construct the logistic regressions, they do pro-
vide reassurance that, in general, the method is performing as
we expected. Further confirmation of this is obtained by looking
at the similar calculation for 44 variants already classified as neu-
tral and not used in either the logistic regression or in the subse-
quent analysis of VUSs. Of these 44 variants, 33 had odds against
being deleterious of 1100:1, and the other 11 all had odds against
being deleterious of a lesser magnitude.
Cosegregation of VUSs in Pedigrees
Elsewhere, we developed a general-pedigree likelihood method
for evaluating cosegregation of variants with disease in families
that can be used to assess disease causality for unclassified se-
quence variants.6 The pedigree likelihood is evaluated under the
hypothesis that the variant under consideration has the same
penetrance as the “average” known deleterious mutation, com-
pared with the hypothesis that the variant segregates indepen-
dent of disease in the pedigree(s) under study.
As part of an effort to assess the clinical significance of VUSs,
individuals found, through the full-sequence testing by Myriad
Genetic Laboratories, to carry a VUS are offered free testing of
additional family members on a research basis. These additional
individuals can be unaffected or affected with BRCA or ovarian
cancer and can be male or female. Typically, only 10% of indi-
vidual probands with VUS provide such samples, and, in most
cases, only one or two samples per family are obtained. The ped-
igree information available in the Myriad Genetic Laboratories
database is somewhat descriptive in nature, and, for this reason,
we used a simplified model of BRCA1/2 penetrance, with seven
liability classes corresponding to (1) unaffected and aged !20
years (or male), (2) unaffected and aged 21–49 years, (3) unaf-
fected and aged 50 years, (4) affected with BRCA at age !50
years, (5) affected with BRCA at age50, (6) affected with ovarian
cancer at age !50, and (7) affected with ovarian cancer at age
50. For each liability class, penetrance values were taken from
the 2003 study of Antoniou et al.,30 by collapsing the incidence
rates across the broader categories used in that study. These ped-
igrees were then analyzed using a modification of the LINKAGE
package,31 as described by Thompson et al.,4 to obtain the re-
quired LR.
Because the analysis of cosegregation relies on the distribution
of the additional genotype data in the pedigree, conditional on
the pedigree (including the proband) phenotypes, it is statistically
independent from the family/personal information. Similarly, the
co-occurrence data is independent from the other two sources,
since individuals who also have known deleterious mutations are
not considered in these analyses. Thus, the three individual LRs
can be multiplied to arrive at a combined LR.
Evaluation of Heterogeneity by Variant Class
To estimate the proportion of mutations in the data set that are
likely to be clinically significant as a function of location, con-
servation, class, etc., we performed a heterogeneity analysis anal-
ogous to that routinely used in linkage analysis. Specifically, the
required likelihood is given by
Nc
aL(DFdeleterious) (1a)L(DFneutral)
ip1
Nc
p aLR (1a) .
ip1
This likelihood (in practice, the log likelihood) is then maxi-
mized over a, and 95% CIs were constructed by finding those
values of that differed by !3.84 from the maxi-2ln(likelihood)
mum value. Hypotheses regarding differences in values of a as a
function of partitions of the total variant space are performed
using likelihood-ratio tests.
The 1,433 variants were subdivided into the following groups:
1. Variants that changed the resulting protein—for example,
MVs and IFDIs;
2. Variants that were extremely likely, on the basis of studies
of many genes and experimental data, to affect splicing,
defined for our purposes as (a) all or (b) if the last1IVS 2
nucleotide of the exon is G and if the first five bases of the
subsequent intron are not GTRAG. Note that the latter set
includes some missense mutations as well as silent substitu-
tions; mutations that were missense changes as well as splice
variants were counted only in the splice variant group.
3. Other variants, consisting primarily of intronic variants not
located within 2 bp of the intron/exon splice junction, ex-
onic variants likely to affect splicing but not meeting the
strict definition above, and also a small number of variants
in the 5′ UTRs and truncating variants at the extreme 3′ end
of the genes.
For the missense/IFDI category, we further subdivided the var-
iants by their location within one of two recognized functional
domains of the proteins: the C-terminus region containing the
BRCA1 BRCT repeats, defined loosely here as “amino acids 1396–
1862,” and the BRCA2 DNA-binding domain (amino acids 2500–
3098). We also categorized these variants according to whether
the wild-type residue involved in the substitution/deletion was
evolutionarily conserved through the pufferfish Tetraodon, using
multiple-sequence alignments constructed by S.V.T.10 and avail-
able on the Align GVGD Web site. In the case of three inframe
insertions, these were denoted as “conserved” if the alignment
across species was stable in the region surrounding the location
of the insertion.
Statistical analyses were performed using STATA version 9.0
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Figure 1. Frequency histogram of combined LLR for 1,433 se-
quence VUSs, by gene (BRCA1 or BRCA2).
Figure 2. Frequency histogram of combined LLR for 1,177 MVs
and IFDIs, by location within either DNA-binding domain (DBD)
of BRCA2, or BRCT domain of BRCA1. For definitions of domains,
see the text. Yesp within DBD/BRCT; nop located outside these
domains.
(StataCorp). The heterogeneity analysis was performed using the
R programming language.
Results
We first built the logistic-regression model comparing pro-
bands found with wild-type BRCA sequence with those
with known deleterious mutations, using the factors de-
tailed in the “Methods” section. As might be expected
with the very large sample sizes used in the analysis, the
logistic regressions were highly significant with good pre-
dictive power; areas under the ROC curve were ∼0.80 for
BRCA1 and ∼0.70 for BRCA2. Not surprisingly, the most
highly significant predictive factors associated with a del-
eterious BRCA1 mutation were associated with personal
and family history of ovarian cancer, with high ORs for
early-onset BRCA as well. For BRCA2, the most important
factors were a personal history of male BRCA and per-
sonal/family history of early-onset BRCA. Interestingly a
strong family history of BRCA diagnosed after age 50 years
was associated with an increased probability of having a
BRCA2 mutation but a decreased risk of carrying a BRCA1
deleterious mutation. For both genes, there were strong
dose-response effects for decreasing age at onset of BRCA
(or ovarian cancer) and also for increasing numbers of
affected relatives. The details of the parameter estimates
are provided in table 2 for the large European sample set;
those for the other two ethnic classifications were broadly
similar. The ethnicity- and gene-specific logistic-regression
equations were then applied to a total of 3,951 family and
personal histories of tested probands found to carry a VUS,
to obtain log-ORs as described in the “Methods” section.
The average number of such scores per variant was 2.76,
with a range of 1–77; over half of the studied variants had
only a single family history available for study. One hun-
dred eighty-two distinct variants had 5 or more family-
history scores; of these, 72 had at least 10 family-history
scores. The associated log-odds of causality per variant
ranged from10.6 to 11.2, with a mean of0.26. Sixteen
variants had total family history log10-likelihood–ratio(LLR)
scores 12, whereas 55 VUSs had scores !2, indicating
odds of 100:1 for and against the variant being deleteri-
ous, respectively, on the basis of the family-history anal-
ysis alone.
In total, 351 pedigrees of probands with 127 (45 BRCA1;
82 BRCA2) distinct variants were analyzed for cosegrega-
tion with disease in families. Odds based on the pedigree
data alone ranged from 138:1 in favor of causality based
on six pedigrees to 1250,000:1 against causality based on
analysis of 17 pedigrees. It should be noted that the var-
iants targeted for this analysis were selected on the basis
of prior evidence that such analysis could contribute to
the likelihood calculation. In the co-occurrence analysis,
121 variants were observed at least once in trans with a
known deleterious mutation, and 21 were observed two
or more times. The LLRs for this source of information
ranged from !8 (for the variant BRCA1*N723D seen 82
times, of which 4 were in trans with a deleterious muta-
tion) to 1.1 (BRCA1*A1708E, seen 76 times, never with a
deleterious mutation). The combined evidence from all
three sources ranged from odds of 11011:1 in favor of dis-
ease causality to 1012:1 against causality.
Figure 1 contains the frequency distribution by gene of
the combined log-odds of causality for the 1,433 VUSs.
From this figure, we see that, whereas 133 variants could
be classified as neutral with odds of 1100:1, only 24 var-
iants (18 BRCA1; 6 BRCA2) achieved this level of classi-
fication in favor of causality. The vast majority of variants
analyzed are relatively uninformative and do not individ-
ually provide information (fig. 1). Figure 2 displays the
distribution of the log-odds of causality for missense and
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Table 3. BRCA Sequence VUSs with Odds of 20:1 in Favor of Causality
Gene and Variant
Family-
History
LLR
LLR
Combined
LLR
Odds in Favor
of CausalityCo-Occurrence Cosegregation
BRCA1:
A1708E 11.22 1.10 .00 12.32 2,110,000,000,000
IVS201GrA 11.11 .52 .00 11.63 431,000,000,000
IVS131GrA 6.09 .60 .00 6.68 4,818,331
R1495M (4603GrT) 5.28 .81 .00 6.10 1,249,808
R1699W 4.34 .26 .00 4.60 39,978
G1788V 2.37 .42 1.06 3.85 7,054
IVS53ArG 3.04 .12 .00 3.15 1,417
G1706E 2.35 .13 .29 2.77 589
IVS19-12GrA 4.52 .10 2.06 2.56 363
L1764P 1.56 .09 .89 2.54 350
V1688del (5181del3) 1.13 .07 1.23 2.43 268
IVS6-3CrG 2.28 .07 .00 2.35 225
IVS151GrA 2.11 .19 .00 2.30 199
IVS171GrA 2.21 .09 .00 2.29 196
T1685I 2.10 .04 .00 2.15 140
I1766S 1.11 .16 .87 2.14 139
G1738R 1.94 .12 .00 2.06 114
T1685A 2.00 .03 .00 2.03 107
IVS6-1GrC 1.84 .01 .00 1.85 72
M1689R 1.49 .17 .00 1.67 46
S1715R 1.56 .09 .00 1.65 45
IVS122del21insA 1.46 .10 .00 1.56 36
M18T 1.41 .09 .00 1.49 31
A1623G (4987CrG) 1.02 .04 .43 1.49 31
IVS11-1GrA 1.36 .01 .00 1.38 24
IVS18-1GrC 1.31 .06 .00 1.37 24
BRCA2:
R2659K (8204GrA) 3.19 .34 .00 3.52 3,339
G2748D 2.41 .16 .83 3.40 2,494
I2627F 2.61 .11 .30 3.02 1,046
E2663V .05 .18 2.14 2.37 233
P3039P (9345GrA) 1.81 .35 .00 2.16 146
D2723G 1.88 .20 .00 2.08 121
IVS15-1GrA 1.51 .46 .00 1.97 94
T2722R .84 .10 1.03 1.97 93
IVS24-1GrC 1.68 .06 .00 1.74 55
R2336H (7235GrA) 1.31 .39 .00 1.70 50
W2626C 1.36 .33 .00 1.68 48
IVS214ArG .35 .13 1.08 1.56 36
L2653P 1.56 .06 .24 1.38 24
D3095E 1.50 .22 .37 1.35 23
IVS5-2ArG 1.26 .07 .00 1.34 22
R2502C .83 .50 .00 1.32 21
IVS191GrA 1.12 .20 .00 1.32 21
Table 4. Variants with Odds of 100:1 in
Favor of Neutrality
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
IFDIs as a function of whether they are located in the BRCT
domain of BRCA1 or the DNA-binding domain of BRCA2.
Although 27 of the 30 variants with odds in favor of cau-
sality 110:1 are in one of these two domains, it should be
noted that 29 variants within these domains have odds
in favor of neutrality of 1100:1.
Table 3 displays the list of all 43 variants with odds in
favor of the VUS being deleterious of at least 20:1, show-
ing each component of the total score and information
on species conservation. Table 4 lists the odds for the 133
variants that have odds of 1100:1 against causality and
thus are likely to be of no or little clinical significance on
the basis of our observations. For those variants with both
family history and cosegregation information, there was
a modest but significant correlation between the log-odds
scores for these two sources ( ; ).rp 0.32 P ! .001
As described in the “Methods” section, we estimated the
proportion of the variants included here that are predicted
to be deleterious in terms of cancer risk, both overall and
in classes of VUSs defined by characteristics on the basis
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Table 5. Heterogeneity Analysis of VUSs by Selected
Characteristics
Variant Class n a (95% CI)
No. of VUSs
with LLR
11.3 !2
All: 1,433 .20 (.16–.25) 43 133
BRCA1 510 .22 (.16–.28) 26 70
BRCA2 923 .18 (.13–.25) 17 63
MV/IFDI: 1,177 .12 (.08–.17) 22 117
Domain:
In BRCT/DBD 323 .35 (.26–.45) 21 29
Other MV/IFDI 854 .0 (.0–.04) 1 88
Sequence Conservation:
Invarianta 218 .46 (.34–.58) 17 14
Variable 959 .03 (.0–.07) 5 103
Splice 79 1.0 (.91–1.0) 14 0
Other 177 .26 (.15–.39) 7 16
a In our alignment of vertebrate BRCA1 and BRCA2 sequences, avail-
able at the Align GVGD Web site.
of mutation type and conservation. These results are shown
in table 5.
Overall, there was no significant difference between
BRCA1 and BRCA2 in the estimated proportion of variants
that were deleterious (likelihood-ratio test, x2 1 ;dfp 0.69
not significant). However, there was significant hetero-
geneity among the three classes of sequence variant (mis-
sense/IFDI, splice, and other) (x2 2 ; );dfp 109.7 P ! .0001
100% of splice-site mutations were estimated to be dele-
terious, compared with 12% of missense/IFDI mutations
and 26% of other unclassified sequence variants. As in the
overall set, no significant differences in the fraction of
MVs estimated to be deleterious were observed between
BRCA1 and BRCA2 variants. A strong association with the
position of the mutation was observed with 35% (95% CI
26%–45%) of mutations within BRCT or DBD domains
estimated to be deleterious, compared with 0% of muta-
tions outside these domains (x2 1 ; ).dfp 56.3 P ! .0001
There was no significant difference in the estimated pro-
portion of deleterious mutations in the BRCA2 DNA-bind-
ing domain (33%) and the BRCA1 BRCT domain (37%).
When mutations were classified by conservation among
species, 46% (95% CI 32%–60%) of the conserved variants
were classified as deleterious, compared with 3% of the
nonconserved substitutions (x2 1 ; ).dfp 59.7 P ! .0001
However, here, we did observe marginally statistically sig-
nificant evidence that a higher proportion of BRCA1 mis-
sense substitutions occurring at strongly conserved posi-
tions were deleterious compared with those of BRCA2
(64% vs. 35%; ).Pp .013
Discussion
Using an approach based on three conditionally indepen-
dent sources of information contained in the Myriad Ge-
netic Laboratories large BRCA testing data set, we evalu-
ated 1,433 sequence variants of unknown clinical signif-
icance in the BRCA susceptibility genes BRCA1 and BRCA2.
Through this analysis, we were able to classify 93 variants
with a threshold of odds of 1,000:1, 157 at 100:1, and
222 with odds of at least 20:1. In each case, the majority
(e.g., 133 of 157 for 100:1 threshold) of VUSs classified
were found to be of no clinical significance with respect
to cancer risk. Although additional BRCA testing data pro-
duced by Myriad Genetic Laboratories, as well as similar
data potentially available from other testing laboratories,
primarily in Europe, could classify additional variants with
use of this approach, it is clear that the majority of variants
are unlikely to be classified in this manner, which high-
lights the need for use of other data. However, it should
be noted that, because the variants most likely to be clas-
sified using our approach are generally the ones with
many observations, the number of families who could
benefit from our results is relatively large. On the basis of
the Myriad database alone and with the assumption of a
threshold for causality of 1,000:1 and for neutrality of 100:
1, as proposed in Goldgar et al.,3 1,569 probands and their
families may now have a more informative test result.
Although only 140 of these are associated with a variant
classified as a deleterious mutation that can be used in
genetics counseling of their families, there is some benefit
for the rest in knowing that they are unlikely to carry a
clinically significant mutation and that their risk is that
conferred by their family history alone.
We emphasize that all the methods used in this article
are based on the assumption that these variants are either
neutral with respect to cancer risks or that they have the
same age- and site-specific risks as the average BRCA mu-
tation as estimated by Antoniou et al.30 If a particular var-
iant were associated with lower penetrance (but still ele-
vated over noncarrier rates), it might provide inconclusive
evidence, even given a large amount of available data, and/
or there would be conflicts between the different sources
of evidence (as well as other such as functional or in silico
studies).
Although most of the information for classification in
this study is derived from the family-history analysis, in
several instances, the three sources were needed to achieve
a clinically useful threshold. For example, the BRCA1 var-
iant I1766S (see table 3) shows odds in favor of causality
of 13:1 from analysis of five family histories, 7.4:1 from
cosegregation analysis of a single pedigree, and 1.44:1 on
the basis of its observation seven times, never with a del-
eterious mutation, yielding overall odds of 139:1 in favor
of this variant being deleterious compared with neutral.
In contrast, the intronic variant BRCA1*IVS19-12GrA
shows convincing odds based on six family histories
(130,000:1), but this conflicts with the pedigree cosegre-
gation data (odds of 115:1 against, on the basis of three
pedigrees); the overall combined evidence for this variant
is 363:1, similar to that for I1766S. The reasons for this
anomaly are unclear. It might reflect an unusual structure
of families from the population from which this variant
derives, or it might reflect some unusual pattern of risks
associated with the mutation that are not well handled
www.ajhg.org The American Journal of Human Genetics Volume 81 November 2007 881
by these methods. To resolve this discrepancy, it would
be helpful to verify the pedigree data and cancer diagnoses
from the original provider/genetics counselor. Addition-
ally, although there are no data from sequence homology
to help in this analysis, in vitro tests of splicing might
also provide data on the pathogenicity of this variant. Of
the different approaches, we regard the cosegregation an-
alysis as the most robust, since it relates directly to the
disease risk and requires few assumptions. Unfortunately,
relatively few variants can be classified by this approach
alone. Our results demonstrate that the family-history
classification can be very powerful, but it is more suscep-
tible to bias due to population-specific ascertainment,8 al-
though this bias may be minimized by appropriate strat-
ification into subgroups with different mutation preva-
lences. This highlights the need for some caution in the
use of these predictions, especially when there are dis-
crepancies between the methods.
Of the 1,433 variants examined, the overall estimate of
the proportion of those that are deleterious was 20%, in-
dicating that perhaps as many as 286 of these variants
could be deleterious mutations. As expected, there was
good evidence that variants predicted to disrupt consensus
splice donors were, as a group, deleterious; in fact, the
estimated proportion of deleterious mutations was 1.0, so
that there was no evidence of neutral variants under the
selection criteria we used. This group accounted for an
estimated 30% of all deleterious variants examined in the
series. Among variants that resulted in a predicted altered
BRCA protein, it was estimated that 12% were deleterious,
and our analyses indicated that most (if not all) deleterious
variants in this group fall at strongly conserved residues
and/or in the recognized domains encompassing the
BRCT repeats in BRCA1 and the DNA-binding domain in
BRCA2. Note that mutations in the ring-finger domain of
BRCA1 have been classified elsewhere as deleterious and
thus are not included in this analysis. As a group, almost
half of all missense substitutions (and IFDIs) falling at po-
sitions that were invariant in our alignments of vertebrate
BRCA1 and BRCA2 sequences were estimated to be dele-
terious; these variants, representing 218 of the 1,433 var-
iants studied, would require odds of causality of 117:1 to
have a posterior probability of 0.99 of being deleterious.
Although we cannot exclude the possibility that VUSs in
nonconserved residues or variants in other parts of the
proteins are deleterious, the upper confidence limits for
these groups indicate that it is unlikely that there are very
many of these, and substantial evidence would be required
to achieve a posterior probability of 0.99 for these variants.
Although there was some slight evidence that the group
of missense substitutions falling at variable residues in-
cludes deleterious substitutions, these were typically cases
where the cross-species sequence variation was conserva-
tive and the substitution falls well outside the evolution-
arily tolerated range of variation. Further, if only the 129
variants falling at invariant positions within the two im-
portant domains are considered, the proportion of vari-
ants that are estimated to be deleterious rises to 0.73 (0.58–
0.86). Among the 177 variants that were located in introns
but not at consensus splice sites, in potential exonic splice
sites, in the 5′ UTR, or at the extreme 3′ ends of the coding
sequence, there was some evidence that this group may
harbor deleterious variants (estimated proportion 26%),
with 9 variants having odds in favor of causality of 110:
1.
For the variants in this analysis, the estimated propor-
tions in table 5 could be used as prior probabilities to
estimate posterior probabilities that each variant is dele-
terious. On the assumption that a posterior probability of
90% would be required to classify a mutation as “probably
deleterious,” missense substitutions (prior probability 0.12)
require odds of 66:1 in favor of causality to be classified.
Ten variants in BRCA1 and five in BRCA2 could be clas-
sified on this basis. The data on species conservation pro-
vide a more precise classification, however. On the basis
of that data, mutations at invariant residues would require
only odds of ∼10:1 to be classified as deleterious—12 var-
iants in BRCA1 and 11 in BRCA2 reach this level. In con-
trast, mutations at variable residues would require odds
of ∼300:1, none of which do so.
Although relatively few variants can currently be clas-
sified, these data can be combined with data from other
sources to provide more-powerful discrimination. These
data could include further pedigree cosegregation data,
but also data on tumor histopathology, which is highly
predictive of BRCA1 mutation status,32 and data on loss
of heterozygosity at the BRCA1 and BRCA2 loci.33,34 This
approach has recently been used for classification of a
small number of BRCA1/2 variants.35–37
The association with sequence conservation and muta-
tion position that we have observed will also be useful for
classification of new variants not present in this data set.
Thus, these data indicate that a novel mutation identified
in a high-risk family will have a substantial probability of
being deleterious only if it occurs in a conserved domain.
Note, however, that the “prior” probabilities given in table
5 refer strictly to the families and variants ascertained in
this database, and their application outside this context
should be undertaken with a degree of caution.
Although many investigators have developed in silico
approaches for classification and have used evaluation of
sequence changes and some have applied functional data,
all of these methods require external validation, and all
have suffered from a lack of such validation. The data we
generated here could serve as a useful source of validation
of such approaches, through repeated sampling of each
variant as neutral or deleterious on the basis of its posterior
probability of causality and then use of the data to esti-
mate parameters of sensitivity and specificity of other
assays.
What is the immediate clinical utility of the results from
the present analyses? Clearly, variants with odds against
causality of 11,000:1 (or even 100:1) could be considered
neutral, rare polymorphisms for the purpose of genetics
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counseling, and the at-risk unaffected family members
who carry such variants would be reassured that they are
not at high risk of BRCA or ovarian cancer due to BRCA1
or BRCA2, although they could still be at increased risk
on the basis of their family history alone. Those who carry
1 of the 10 variants for which the evidence achieves the
threshold of 1,000:1, or perhaps the 48 (36 of which are
at splice sites) with posterior probabilities 10.99, should
logically be offered the same options as carriers of BRCA-
truncating mutations. Apart from those variants that meet
these thresholds, will it be useful to report intermediate
categories of risk, such as “likely deleterious” or “probably
neutral,” or should the current odds in favor of or against
causality be reported to the provider? These questions will
require consideration by specialists in risk communication
and other disciplines and, as such, are beyond the scope
of this study. Our goal in this effort is to eventually classify,
with such information, a large number of variants as either
“deleterious” or “neutral” and to incorporate the evidence
behind the classification as part of the BIC database, as a
centralized resource for clinicians and researchers alike.
We feel that, with a systematic approach such as this, the
problems of clinical interpretation and patient recommen-
dations caused by these heretofore “uncertain” variants
can be minimized.
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